ChemoCentryx Stock Jumps On Amendment In Avacopan Application, New Goal Date Of October 7
InflaRx's Vilobelimab Hits Primary Endpoint Goal In Late-Stage ANCA-Associated Vasculitis Study
ChemoCentryx Stock Jumps On Amendment In Avacopan Application, New Goal Date Of October 7
InflaRx's Vilobelimab Hits Primary Endpoint Goal In Late-Stage ANCA-Associated Vasculitis Study
Adcomm Split On FDA Approval For ChemoCentryx's Vasculitis Candidate
ChemoCentryx Stock Plunges As FDA Briefing Document Casts Doubt On Vasculitis Candidate Avacopan's Data